The MDT-BRIDGE trial's 142-patient neoadjuvant durvalumab dataset introduces a multidisciplinary reassessment architecture ...
EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer, with strong disease control across histology subtypes ...
Kos Biotechnology Partners funds Golden Age Health to accelerate rare disease access in Asia, closing treatment delays for ...
ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis trial, with potential for once-yearly dosing in ...
Citius Oncology reports preliminary LYMPHIR unit sales and vial orders for Q4 2026, signaling commercial momentum in the ...
Medrio's Early Adopter Program offers three tiers of discounted access to clinical trial software, with Level 2 participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results